Synpromics

Michael Roberts Ph.D., Founder and Chief Scientific Officer
Edinburgh, UK
(Private)

Synpromics gives researchers, developers and manufacturers unprecedented control of gene expression through proprietary technology that yields highly specific and active synthetic promoters. The company’s patentable synthetic promoters are designed to regulate genes in a customized manner and help facilitate a competitive IP position for Synpromics’ partners. Given that these promoters greatly improve upon the viral and natural promoters on which the cell and gene therapy industry currently relies, there is enormous potential for the technology to help drive the industry forward and transform the entire sector.